P4, N=175, Recruiting, Orszagos Onkologiai Intezet | Not yet recruiting --> Recruiting

The patient received combination chemotherapy with gemcitabine, carboplatin, and bevacizumab, achieving a near-complete metabolic response. Immunohistochemistry plays a crucial role in identifying the primary tumor origin. Management requires a staged approach with emergency surgical intervention followed by multidisciplinary oncological treatment for optimal outcomes.

ICIs included standard programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) antibodies, chemotherapy was platinum-based doublet therapy, and anti-angiogenic therapy was limited to bevacizumab (BEV)...ICIs + CHE is the preferred first-line treatment regimen for patients with locally advanced/metastatic KRAS-mutant non-squamous NSCLC, and the addition of anti-angiogenic agents does not improve therapeutic efficacy. Clinical treatment regimens should be selected individually based on patient characteristics and PD-L1 expression level did not serve as a survival stratification factor for immunotherapy-based treatment regimens.

Immunotherapy with atezolizumab (1200 mg every 3 weeks [Q3W]) combined with targeted therapy with bevacizumab (600 mg Q3W) was initiated in July 2021.A substantial temporal gap of approximately 21 months followed, after which electroacupuncture-based rehabilitation (5-Hz continuous-wave, stimulating Jiaji acupoints, Zusanli, etc) was started in May 2023. Targeted immunotherapy combined with electroacupuncture may influence neural remodeling by modulating a pro-reparative inflammatory microenvironment, which could potentially support functional reconstruction in patients with spinal metastases. However, there is no direct evidence that immunotherapy accelerates neural recovery, and these observations should be interpreted as hypothesis-generating findings requiring rigorous testing in prospective studies.

The use of bevacizumab, an antiangiogenic agent for targeting VEGF, has been associated with a potentially high rate of side effects in the treatment of different types of tumors...DPPA inhibits tumor neovascularization might through regulating interferon γ (IFN-γ)-related signaling, which can further activate CXCL9/10/11-chemokine receptor 3 (CXCR3) signaling. Our findings suggest that DPPA has the potential to serve as an effective antiangiogenic agent for the treatment of MM.

For OS, both cetuximab + chemotherapy [hazard ratio (HR)=0.853; 95% CI: 0.775-0.938; P=0.001] and panitumumab + chemotherapy (HR=0.855; 95% CI: 0.738-0.992; P=0.038) exhibited statistically significant superiority compared with bevacizumab + chemotherapy...In the present sensitivity analysis, UDP glucuronosyltransferase family 1 member A1-guided bevacizumab + 5-fluorouracil, leucovorin and irinotecan demonstrated favorable outcomes, with OS and PFS P-scores of 0.932 and 0.992, respectively; however, these findings were derived from a single trial with limited comparability...Treatment benefit from anti-EGFR therapy was markedly influenced by primary tumor location, with notable benefit observed in left-sided tumors and no benefit in right-sided tumors. These findings support tumor sidedness-guided treatment selection in clinical practice, favoring anti-EGFR-based therapy for left-sided and bevacizumab-based therapy for right-sided RAS wild-type mCRC.

P3, N=244, Recruiting, University Hospital, Tours | Not yet recruiting --> Recruiting | Trial completion date: Oct 2029 --> Mar 2029 | Trial primary completion date: Oct 2028 --> Mar 2028

We report the case of a 58-year-old woman receiving atezolizumab and bevacizumab for hepatocellular carcinoma who developed new-onset polyuria and polydipsia followed by diabetic ketoacidosis within weeks of commencing immunotherapy. This case adds to the growing literature on programmed death-ligand 1 inhibitor-induced diabetes in the hepatocellular carcinoma population, where such events are incompletely characterised. Clinicians managing patients on atezolizumab-based regimens should maintain a low threshold for glucose monitoring and early ketone testing in the presence of osmotic symptoms.

P1, N=10, Enrolling by invitation, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2022 --> Dec 2029 | Trial primary completion date: Jan 2021 --> May 2029

P2, N=120, Not yet recruiting, Shandong University

PRef to A+B identifies a distinct biological entity characterised by unopposed systemic inflammation, myeloid infiltration and T-cell depletion. Targeting myeloid-mediated immunosuppression, particularly in patients with low IFN-γ signature expression and elevated NLR might enhance responsiveness to A+B.

The E + B combination showed modest anti-tumor activity in patients with heavily pretreated EGFR-amplified solid cancers. While NGS may help identify new applications for existing drugs, additional investigations are warranted to validate the efficacy and benefit of E + B in this population.